NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive Sponsors SOLAS 2018, Hosts Workshop On Latest Lateral Innovations

SAN DIEGO, May 16, 2018 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced that the Company is a sponsor of the Society of Lateral Access Surgery (SOLAS) and its annual meeting being held May 17-19, 2018, in San Diego. NuVasive was recently recognized by SOLAS for its longstanding commitment and the first-ever Global Partner in its new partnership program this year.

NuVasive Logo

NuVasive founded SOLAS in 2006 and proudly continues as a sponsor of the organization as an independent medical society. The mission of SOLAS is to advance minimally disruptive lateral access spine surgery techniques through clinical research, peer-to-peer education and membership initiatives. This aligns with the NuVasive focus of developing minimally-invasive, lateral spine solutions—including Lateral Single-Position Surgery™—that empower surgeons to create positive clinical outcomes that improve patients' lives.

During the Annual SOLAS Meeting, NuVasive will host an industry workshop, Leading. Expanding. Advancing. Lateral Solutions and Technologies in the Lumbar Spine, on May 18 from 12:30-2:00 p.m. led by surgeon faculty J. Alex Thomas, M.D., Brian Kwon, M.D. and Gregory M. Mundis, M.D. This is a non-CME, industry-sponsored educational program. For more information, visit the SOLAS Program.

"We are pleased to participate in the SOLAS partnership program and have the opportunity to host a workshop among this group of lateral-focused surgeons," said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. "The research and education that has come out of SOLAS over the last 12 years has been invaluable in the clinical advancement of the lateral approach. As SOLAS continues to build on their strong academic, educational and scientific foundation, it is great to see other companies recognize the importance of this organization and join us as partners to help SOLAS further its mission."

The NuVasive exhibit will focus on a variety of spine solutions, including Lateral Single-Position Surgery, the SpineTRACK Registry and The Better Way Back® Program.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/nuvasive-sponsors-solas-2018-hosts-workshop-on-latest-lateral-innovations-300646826.html

SOURCE NuVasive, Inc.

Investor Contact, Suzanne Hatcher, NuVasive, Inc., 858-458-2240, investorrelations@nuvasive.com or Media Contact, Troy Anderson, NuVasive, Inc., 858-349-6983, media@nuvasive.com